CD8A and non-small cell lung carcinoma: Next, we investigated whether the levels of circulating CD8+MAIT and CXCR6+CD8+MAIT cells affected clinical prognosis as predictive biomarkers of the response to anti-PD-1 therapy in NSCLC.